Interview with Mats Nilsson, serial entrepreneur at SciLifeLab


Sciety had the opportunity to ask a few questions to Mats Nilsson, professor at SciLifeLab and co-founder of EMPE Diagnostics and several other biotechnology companies. In the interview he talks about EMPE Diagnostics’ planned establishment in India and and about the need for diagnostic tools in order to use the drugs that are available. He gives an insight into SciLifeLab as the platform for developing ideas and also his view on the role of research in society.

Read more

The Sciety syndicate invests in Synartro that develops a novel drug for osteoarthritis


The Sciety syndicate invests in Synartro, which uses existing drugs with proven efficacy to develop an improved drug treatment of knee osteoarthritis. The new capital will be used to complete the pre-clinical development. The company plans to go public to raise capital for phase 1 clinical trials in 2021. Synartro’s…

Read more

Interview with Pavan Asalapuram, the founder of EMPE Diagnostics


Hi Pavan! Tell us about the idea and vision of EMPE Diagnostics? “Our idea is to develop DNA-based diagnostics that are suitable for resource limited clinical laboratories in low- and middle-income countries. We have integrated proven technology for diagnosis of infectious diseases with technology that allows test results to be…

Read more

The Sciety syndicate invests MSEK 9.1 in a cardiovascular diagnostic company


The Sciety investor syndicate recently made an investment of MSEK 9.1 in the company Cavis Technologies, which has developed Wirecath®, a patent-pending product for the diagnosis of coronary heart diseases. The new capital will be used to establish sales on the European market. “Only in Europe, over 1.5 million people…

Read more

New diagnostic technology can reduce mortality in one of the world’s most common infectious diseases


Today, Sciety wants to pay attention to World TB Day, which aims to highlight the extensive health, social and economic consequences of tuberculosis. Tuberculosis is a contagious infectious disease that primarily affects the lungs but also other organs. It is an airborne disease that spreads from one person to another…

Read more

Sciety invests in cancer diagnostics of the future with Industrifonden


Sciety invests SEK 35 million in Elypta, a diagnostic company developing a new technology for early cancer diagnosis. The Sciety investment syndicate together with the Swedish venture capital fund Industrifonden, Chalmers Ventures and several of the company’s existing owners participated in this investment round. The new capital amounting to SEK…

Read more

Sciety network invests in Predicare- the company making emergency care more effective


Sciety network has now completed an investment of MSEK 9 in Predicare who has developed RETTS, a system used by the majority of Sweden’s emergency units. The new capital will be used for expansion into selected European markets and a further development of the company’s product portfolio. The Gothenburg based…

Read more

EMPE Diagnostics raises MSEK 9 for its launch in India


This week EMPE Diagnostics completed a new share issue of a total of MSEK 9.2. The company has developed a quick test for tuberculosis and the new capital will support the establishment of operations in India where tuberculosis is a major health problem. “With the new capital, we will establish…

Read more

The Sciety network invest MSEK 15 in state-of-the-art DNA sequencing company


This week, Single Technologies completed a new share issue of MSEK 15 with Sciety. The company has developed a DNA sequencing solution making possible quicker and cheaper analysis of large data volumes. The new capital will be used to adapt the instrument for NGS analysis where the company already has…

Read more

Athera Biotechnologies raises MSEK 55 with the help of Sciety


This week, pharmaceutical company, Athera Biotechnologies, completed a new share issue of MSEK 55 in which Industrifonden, Östersjöstiftelsen and the Sciety network participated. The new capital is to be used for a clinical Phase 2 study and the company aims at being acquired by a major player after the study…

Read more